Descripción del proyecto
Un nuevo papel de los agonistas del receptor de la nischarina para el tratamiento del cáncer pancreático
El adenocarcinoma pancreático ductal (PDAC, por sus siglas in inglés) es uno de los tipos más letales de cáncer y presenta una supervivencia a cinco años inferior al 5 %. El objetivo del proyecto financiado con fondos europeos REPANCAN es reducir el elevado coste y los prolongados plazos de desarrollo de nuevos medicamentos utilizando el concepto de reposicionamiento de fármacos para una clase de agonistas del receptor de la nischarina. Ya se había demostrado que el receptor de la nischarina presenta actividad de supresión tumoral en el cáncer de mama, y sus agonistas podrían actuar sobre la capacidad de invasión celular, la supervivencia, el metabolismo y el microentorno tumoral asociados con el PDAC. El proyecto combinará enfoques de la bioinformática y la investigación molecular y celular con el objetivo de establecer una base para el reposicionamiento de fármacos de bajo coste y con un perfil de seguridad probado para tratar uno de los tipos de cáncer más letales a la vez que menos estudiados.
Objetivo
The main objective of the REPANCAN is to integrate Jelena Grahovac, PhD at the Institute for Oncology and Radiology of Serbia, as a leader of a project that will address an urgent unmet need for new treatment strategy for patients with pancreatic ductal adenocarcinoma (PDAC). PDAC is one of the most lethal types of cancer in the world, with a 5-year survival rate of less than 5% and an increasing incidence rate. Research on PDAC is limited and progress in patient survival has not been made in the last 40 years. To circumvent the high costs and long development times for new oncological drugs, the REPANCAN project will use the drug repurposing concept and establish a novel use for a class of nischarin (NISCH) receptor agonists. NISCH receptor itself has been shown to be a tumor suppressor in breast cancer and its agonists hold promise for targeting several aspects of the PDAC pathology: cell invasiveness, survival, metabolism, and the microenvironment. To address the acute demand for novel PDAC therapy, the REPANCAN project will integrate the bioinformatic, molecular and cellular research with the retrospective patient study though 3 research objectives: 1) Examination of levels of NISCH in patient tumor samples and in vitro model systems, 2) Establishment of mechanisms by which clinically approved NISCH agonists can limit PDAC growth and 3) Retrospective analysis of effects of NISCH agonist treatment on PDAC progression in patients. To strengthen the competence of Dr Grahovac and use cutting edge technologies in REPANCAN, a secondment at Dr Peter Carmeliet’s laboratory at VIB-KU Leuven is planned. REPANCAN will establish a novel prognostic marker, novel drug target and a ground for repurposing of low-cost drugs proven to be safe in one of the most lethal and understudied types of cancer.
Ámbito científico
- medical and health sciencesclinical medicineoncologyprostate cancer
- medical and health sciencesclinical medicineradiology
- medical and health sciencesclinical medicineoncologybreast cancer
- medical and health sciencesbasic medicinepathology
- medical and health sciencesclinical medicineoncologypancreatic cancer
Palabras clave
Programa(s)
Régimen de financiación
MSCA-IF - Marie Skłodowska-Curie Individual Fellowships (IF)Coordinador
11000 Belgrade
Serbia